BIOMAT Database Logo BIOMAT Database Logo

[Controlled trial of cyclophosphamide, azathioprine and chlorambucil in lupus nephritis (the double-blind method)]. 1981

M M Ivanova, and V A Nasonova, and S K Solov'ev, and V D Akhnazarova, and A I Speranskiĭ

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009393 Nephritis Inflammation of any part of the KIDNEY. Nephritides
D002699 Chlorambucil A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed) 4-(Bis(2-chloroethyl)amino)benzenebutanoic Acid,Amboclorin,CB-1348,Chloraminophene,Chlorbutin,Leukeran,Lympholysin,N,N-Di-(2-chloroethyl)-p-aminophenylbutyric Acid,NSC-3088,CB 1348,CB1348,NSC 3088,NSC3088
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females

Related Publications

M M Ivanova, and V A Nasonova, and S K Solov'ev, and V D Akhnazarova, and A I Speranskiĭ
A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis.
January 1974, Arthritis and rheumatism,
M M Ivanova, and V A Nasonova, and S K Solov'ev, and V D Akhnazarova, and A I Speranskiĭ
Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial.
August 2006, Kidney international,
M M Ivanova, and V A Nasonova, and S K Solov'ev, and V D Akhnazarova, and A I Speranskiĭ
Comparison of chlorambucil, azathioprine or cyclophosphamide combined with corticosteroids in the treatment of lupus nephritis.
February 1979, The British journal of dermatology,
M M Ivanova, and V A Nasonova, and S K Solov'ev, and V D Akhnazarova, and A I Speranskiĭ
Cyclophosphamide in lupus nephritis: a controlled trial.
August 1971, Annals of internal medicine,
M M Ivanova, and V A Nasonova, and S K Solov'ev, and V D Akhnazarova, and A I Speranskiĭ
Azathioprine, cyclophosphamide and chlorambucil.
December 1990, Bailliere's clinical rheumatology,
M M Ivanova, and V A Nasonova, and S K Solov'ev, and V D Akhnazarova, and A I Speranskiĭ
Fish oil enhanced the efficacy of low-dose cyclophosphamide regimen for proliferative lupus nephritis: a randomized controlled double-blind trial.
January 2021, Food & nutrition research,
M M Ivanova, and V A Nasonova, and S K Solov'ev, and V D Akhnazarova, and A I Speranskiĭ
EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.
May 2004, Annals of the rheumatic diseases,
M M Ivanova, and V A Nasonova, and S K Solov'ev, and V D Akhnazarova, and A I Speranskiĭ
Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis.
June 1982, Annals of internal medicine,
M M Ivanova, and V A Nasonova, and S K Solov'ev, and V D Akhnazarova, and A I Speranskiĭ
Azathioprine: a controlled, double-blind trial in rheumatoid arthritis.
May 1969, Annals of the rheumatic diseases,
M M Ivanova, and V A Nasonova, and S K Solov'ev, and V D Akhnazarova, and A I Speranskiĭ
Azathioprine in active chronic iridocyclitis. A double-blind controlled trial.
May 1969, The British journal of ophthalmology,
Copied contents to your clipboard!